| Literature DB >> 30077181 |
Cécile Aubron1,2, Andrew W J Flint3,4, Yves Ozier5, Zoe McQuilten3,6.
Abstract
BACKGROUND: Platelets (PLTs) are usually stored for up to 5 days prior to transfusion, although in some blood services the storage period is extended to 7 days. During storage, changes occur in both PLT and storage medium, which may lead to PLT activation and dysfunction. The clinical significance of these changes remains uncertain.Entities:
Keywords: Allogeneic transfusion; Complication; Critically ill patients; Efficacy; Haematology patients; Platelet storage
Mesh:
Year: 2018 PMID: 30077181 PMCID: PMC6091146 DOI: 10.1186/s13054-018-2114-x
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1Endpoints to evaluate safety and efficacy of stored PLTs. RBC red blood cell, PLT platelets, CCI corrected count increment, PLT CI platelet count increment
Fig. 2Review flow chart
Studies analysing the potential association between PLT storage duration and clinical or transfusion outcomes in critically ill patients
| Study | Population | Study design | PLT characteristics and maximum storage duration | Primary outcome | Secondary outcome | Analyses/comparator | Main results |
|---|---|---|---|---|---|---|---|
| Welsby et al. [ | Cardiac surgery, 2578 patients | Retrospective single centre | Leucoreduced | 30-day mortality or hospital stay > 10 days | Infections | All patients | No association |
| Inaba et al. [ | Trauma, 381 patients | Retrospective two-centre | Apheresis | Mortality | Sepsis | Patients with only PLTs stored for ≤ 3 days, 4 days and 5 days | No association with mortality |
| Juffermans et al. [ | ICU, 134 patients | Retrospective single centre | Leucoreduced WBD, buffy coat derived | Nosocomial infections | – | Number of PLTs > 4 days | No association |
| Juffermans et al. [ | Trauma, 196 patients | Retrospective single centre | Leucoreduced WBD, buffy coat derived | Nosocomial infections | – | Number of PLTs > 4 days | No association |
| Flint et al. [ | ICU, 1430 patients | Retrospective two-centre | Leucoreduced Apheresis and WBD, buffy coat derived | Mortality | Blood stream infections and bacteriuria | All patients and patients receiving only one PLY unit | No association |
Abbreviations: ARDS acute respiratory distress syndrome, AKI acute kidney injury, PLT CCI platelet corrected count increment, ICU intensive care unit, LOS length of stay, WBD whole blood derived, PLT platelet, PLT CI platelet count increment
aPLT storage duration not specified
Studies analysing the potential association between PLT storage duration and clinical or transfusion outcomes in haematology or oncology patients
| Study | Population | Study design | PLT characteristics and maximum storage duration | Primary outcome | Secondary outcome | Analysis/comparator | Main results |
|---|---|---|---|---|---|---|---|
| Van Rhenen et al. [ | Haematology | Propsective observational study for the review outcomea | Leucoreduced WBD, buffy coat derived | 1-h CCI | 24-h CCI | Up to 5 days | Association between PLT storage time and 1 and 24-h CCI |
| Dijkstra-Tiekstra et al. [ | Haematology | Prospective observational single centre | Leucoreduced, WBD, buffy coat derived | 1-h CI ≥ 10 | 1-h CCI | 2, 3, 4, 5, 6 and 7 days | No difference between 5 and 7 days of storage; PLTs stored for 2 days had higher 1-h CCI than PLTs stored for 7 days |
| Slichter et al. [ | Haematology | Post hoc analysis of a randomised trial | Apheresis and WBD, plasma rich preparation | 1- and 24-h CCI | Time to next transfusion | 2, 3, 4 and 5 days Analysis per transfusion | PLTs stored less than 48 h were associated with better 1- and 24-h CCI and s longer time to next transfusion |
| Akkok et al. [ | Haematology | Prospective observational, two-centre | Leucoreduced | 1-h CCI | 18–24 h CCI | Up to 6.5 days | Decrease in 1- and 24-h CCI and time to next transfusion when storage time increased |
| Heim et al. [ | Haematology | Prospective observational | Apheresis | 1- and 24-h CCI | TRAE | Up to 5 days | PLTs stored for ≥ 3 days were associated with a lower CCI |
| Diedrich et al. [ | Haematology | Double blind randomised, single centre | Leucoreduced | 1- and 24-h CCI | Time to next PLT transfusion | Storage duration:1 to 5 days versus 6 to 7 days | Higher CCI and longer time to next transfusion in the group “fresher PLT” |
| Kerkhoffs et al. [ | Haemato-oncology | Prospective multicentre observational study for the review outcomesa | Leucoreduced, WBD, buffy coat derived | 1-h CCI | 24-h CCI RBC number | Up to 7 days | Storage time was associated with 1- and 24-h CCI but not with bleeding |
| Triulzi et al. [ | Haematology | Post hoc analysis of a multicentre RCT | Apheresis or WBD plasma rich preparation | Clinical bleeding (time from first transfusion to first ≥ grade 2 bleeding) | Absolute PLT | Age of PLTs of the first transfusion | No association between PLT storage duration and bleeding |
| Heuft et al. [ | Haematology | Retrospective single centre | Apheresis PLTs | 24-h CCI | Time to next transfusion | Max 4 days versus 3 days | Fresher PLTs were associated with higher CCI and less bleeding |
| Dijkstra-Tiekstra et al. [ | Onco-haematology | Prospective observational, three-centre | WBD, buffy coat derived | 1- and 24-h CCI | – | 2, 3, 4, 5, 6, 7 days | No association |
| MacLennan et al., [ | Haematology | Crossover blocked randomised trial; 2 to 5 days versus 5 to 7 days | Apheresis and WBD buffy coat derived, leucoreduced | CCI > 4.5 between 8 to 24 h | CCI | Mean age 3.8 days (SD1.0) versus 6.4 (0.5) days | No effect of the age of PLTs on primary outcome and bleeding |
| Kaufman et al. [ | Haematology | Post hoc analysis of a multicentre RCT | Apheresis or WBD plasma rich preparation, leukoreduced | TRAE | TRAE considered separately | 0–2 days, 3 days, 4 days versus 5 days as reference | No association |
| Kaplan et al. [ | Haematology | Retrospective single centre study | WBD riboflavin based PRTs | 24-h PLT CI | TRAE | Up to 5 days versus 6–7 days | No association |
Abbreviations: CCI corrected count increment, WBD whole blood derived, RCT randomised controlled trial, PAS platelet additive solution, PLT platelet, PLT CI, platelet count increment, PRT pathogen reduction technology, SD standard deviation, TRAE transfusion-related adverse events, WHO World Health Organisation
aThese studies are randomised trials, but randomisation was not performed by PLT storage duration; therefore, they are considered as observational studies
Impact of storage duration on corrected count increment and time to next transfusion in haematology patients
| Study | 1–24 h CCI | Time to next transfusion (days) |
|---|---|---|
| Van Rhenen et al. [ | Decrease in CCI with increased storage time | – |
| Dijkstra-Tiekstra et al. [ | Decrease in CCI with increased storage time | – |
| Slichter et al. [ | Decrease in CCI with increased storage time | – |
| Akkok et al. [ | Decrease in CCI with increased storage time | Decreased time to next transfusion with decrease in storage time |
| Heim et al. [ | Decrease in CCI with increased storage time (hazard ratio 1.201, 95% confidence interval 1.065–1.354, | – |
| Diedrich et al. [ | Decrease in CCI with increased storage time (mean 5.4 ± 4.1 versus 2.6 ± 2.6, | Decreased time to next transfusion with decrease in storage time (mean time 2.2 ± 1.1 days versus 1.6 ± 0.8 days, |
| Kerkhoffs et al. [ | Decrease in CCI with increased storage time | – |
| Triulzi et al. [ | Decrease in CCI with increased storage time | No association |
| Heuft et al. [ | Decrease in CCI with increased storage time (median 8.3 [IQR 3.9–13.1] versus 3.5 × [IQR 1.5 10.0], | Decreased time to next transfusion with decrease in storage time (median 1.1 day versus 2 days, |
| Dijkstra-Tiekstra et al. [ | Decrease in CCI with increased storage time | – |
| MacLennan et al., [ | No association | No association |
| Kaplan et al. [ | No association | – |
Abbreviations: CCI corrected count increment, IQR interquartile ranges
Bias assessment of the randomised controlled trials included in this review
| Study | Allocation concealment | Random sequence generation | Blinding (participant, physician) | Blinding (outcome) | Incomplete outcome data | Selective reporting | Other |
|---|---|---|---|---|---|---|---|
| Diedrich et al. [ | Low risk | Unclear | Low risk | Low risk | Low risk | Low risk | Similar number excluded due to wrong PLT storage time each arm |
| MacLennan et al. [ | Low risk | Low risk | Unclear risk | Low risk | Low risk | Low risk | Off protocol transfusion |
Bias assessment for primary outcomes of included observational studies
| Study | Bias due to confounding | Selection bias | Bias due to classification of interventions | Deviation from protocol | Missing data | Measurement of outcomes | Selective reporting | Overall risk of bias |
|---|---|---|---|---|---|---|---|---|
| Outcome: mortality | ||||||||
| Welsby et al. [ | Moderate risk | Low risk | Low risk | Low risk | Low risk | Low risk | Moderate risk | Moderate risk |
| Inaba et al. [ | Moderate risk | Low risk | Low risk | Low risk | Unclear risk (no information) | Low to moderate risk | Moderate risk | Moderate risk |
| Flint et al. [ | Moderate risk | Low risk | Low risk | Low risk | Low risk | Low risk | Moderate risk | Moderate risk |
| Outcome: nosocomial infections | ||||||||
| Juffermans et al. [ | Moderate risk | Low risk | Low risk | Low risk | Unclear risk (no information) | Low risk | Moderate risk | Moderate risk |
| Juffermans et al. [ | Moderate risk | Low risk | Low risk | Low risk | Unclear risk (no information) | Low risk | Moderate risk | Moderate risk |
| Outcome: bleeding | ||||||||
| Triulzi et al. [ | Moderate risk | Low risk | Low risk | Low risk | Low risk | Low risk | Moderate risk | Moderate risk |
| Outcome: CCI | ||||||||
| Kerkhoffs et al. [ | Moderate risk | Low risk | Low risk | Low risk | Low risk | Low risk | Moderate risk | Moderate risk |
| Dijkstra-Tiekstra et al. [ | Serious risk | Low risk | Low risk | Low risk | Moderate risk | Low risk | Moderate risk | Serious risk |
| Van Rhenen et al. [ | Moderate risk | Low risk | Low risk | Low risk | Low risk | Low risk | Moderate risk | Moderate risk |
| Heuft et al. [ | Serious risk | Low risk | Low risk | Low risk | Low risk | Moderate risk | Moderate risk | Serious risk |
| Slichter et al. [ | Moderate risk | Low risk | Low risk | Low risk | Low risk | Low risk | Moderate risk | Moderate risk |
| Akkok et al. [ | Moderate risk | Low risk | Low risk | Low risk | Low risk | Low risk | Moderate risk | Moderate risk |
| Heim et al. [ | Moderate risk | Low risk | Low risk | Low risk | Unclear risk (no information) | Low risk | Moderate risk | Moderate risk |
| Dijkstra-Tiekstra et al. [ | Moderate risk | Low risk | Low risk | Low risk | Low risk | Low risk | Moderate risk | Moderate risk |
| Outcome: PLT CI | ||||||||
| Kaplan et al., [ | Serious | Low risk | Low risk | Low risk | Unclear risk | Low risk | Moderate risk | Serious risk |
| Outcome: TRAE | ||||||||
| Kaufman et al. [ | Moderate risk | Low risk | Low risk | Low risk | Low risk | Low to moderate risk | Moderate risk | Moderate risk |
Abbreviations: CCI corrected count increment, PLT CI platelet count increment, TRAE transfusion-related adverse events